Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0RV0O
|
|||
| Drug Name |
PMID29334795-Compound-23
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Patented | [1] | |
| Company |
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED WANG, Rong LU, HongtaGLAXO GROUP LIMITED BAMFORD, Mark, James DEAN, David, Kenneth SEHMI, Sanjeet, Singh WILSON, David, Matthew WITHERINGTON, Jason
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27N3O2
|
|||
| Canonical SMILES |
C1CC(C1)N2CCC3=C(CC2)C=C(C=C3)OC4=NC=C(C=C4)N5CCCC5=O
|
|||
| InChI |
1S/C23H27N3O2/c27-23-5-2-12-26(23)20-7-9-22(24-16-20)28-21-8-6-17-10-13-25(19-3-1-4-19)14-11-18(17)15-21/h6-9,15-16,19H,1-5,10-14H2
|
|||
| InChIKey |
YFRBKEVUUCQYOW-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 720691-69-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H3 receptor (H3R) | Target Info | Inverse agonist | [1] |
| Target's Patent Info | Histamine H3 receptor (H3R) | Target's Patent Info | [1] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Reactome | Histamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine Transport | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017).Expert Opin Ther Pat. 2018 Mar;28(3):175-196. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.